Apellis Pharmaceuticals, Inc. filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company with common stock registered under the Exchange Act. The company’s 8-K reports cover product revenue disclosures for SYFOVRE and EMPAVELI, cash and financial-condition updates, and material agreements related to collaborations, royalty arrangements, financing consents, and strategic transaction activity.
Apellis filings also record governance and compensation matters, including board appointments, director compensation, executive separation and retention plans, and related equity-award provisions. These documents disclose formal corporate actions, capital-structure references, material-event reporting, and the company’s public-company obligations as a Delaware issuer.
Apellis Pharmaceuticals (APLS) Q2-25 10-Q highlights: Net revenue fell 11% YoY to $178.5 M, driven by slightly lower SYFOVRE sales ($150.6 M vs. $154.6 M) and a sharper drop in EMPAVELI ($20.8 M vs. $24.5 M). Licensing & other revenue added $7.1 M. Six-month revenue declined 7% to $345.3 M.
Profitability: Gross margin remained high; cost of sales decreased 41% to $13.6 M. Expense discipline lowered R&D 14% to $67.0 M; however, SG&A rose 2% to $131.1 M. Operating loss widened to $33.3 M and net loss to $42.2 M (-$0.33/sh). First-half net loss reached $134.4 M, vs. $104.1 M in 1H-24.
Balance sheet: Cash & equivalents ended at $370.0 M (vs. $411.3 M YE-24). Long-term debt totals $469.0 M (credit facility $375 M, converts $93.9 M). Equity fell to $156.3 M from $228.5 M on cumulative losses.
Liquidity & subsequent event: Management believes existing cash plus a $275 M upfront payment from Sobi (Royalty Buy-Down signed 1 Jul 25) and ongoing product sales fund operations for ≥12 months.
Operational notes: Inventory rose to $169.1 M; product-sales reserves $44.5 M. Customer D represents 62% of Q2 gross revenue. Development of systemic pegcetacoplan for TA-TMA discontinued post-quarter.
Key per-share data: Weighted-avg shares 126.0 M; net loss/share -$0.33 vs. -$0.30 YoY.
On 1 July 2025, Apellis Pharmaceuticals (NASDAQ: APLS) filed an 8-K announcing a Royalty Buy-Down Agreement with Swedish Orphan Biovitrum (Sobi).
- Up-front consideration: Sobi will pay Apellis $275 million in cash within five business days of closing.
- Milestone: Up to $25 million becomes payable upon European Medicines Agency (EMA) approval of Aspaveli for C3G and IC-MPGN.
- Royalty reduction: In exchange, Apellis will reduce Sobi’s royalty obligations under their October 2020 collaboration by 90 %, effective immediately.
- Royalty cap: The discount lasts until cumulative reduced royalties equal 1.45× the total amounts paid under the new agreement; thereafter, the original royalty rates resume.
- Lender consent: Sixth Street Lending Partners consented to the deal. As a condition, Apellis extended by one year the period during which prepayment premiums apply on its May 13 2024 credit facility.
The transaction delivers up to $300 million in non-dilutive liquidity, strengthening Apellis’ near-term cash position while delaying—but not eliminating—future royalty income from Aspaveli in Sobi territories. The 1.45× cap preserves long-term upside once Sobi recovers its investment. Investors should weigh immediate balance-sheet relief against the temporary 90 % royalty haircut and the extended prepayment-premium window on existing debt.
Apellis Pharmaceuticals, Inc. (APLS) filed a Form 4 disclosing that its Vice President & Chief Accounting Officer, James George Chopas, received a grant of 6,250 shares of common stock in the form of restricted stock units (RSUs) on 18 June 2025. The transaction was coded “A(1),” indicating an award under the company’s equity compensation plan at no cash cost to the executive (reported price $0). Following the grant, Chopas’ total beneficial ownership increased to 54,205 shares held directly.
The RSUs vest over a two-year period: 50 % on the first anniversary of the grant date and the remaining 50 % on the second anniversary, contingent upon continued employment. No derivative securities were acquired or disposed of, and the filing does not reference any Rule 10b5-1 trading plan. The filing was signed on 20 June 2025 by attorney-in-fact David Watson.
From an investor perspective, this is a routine executive equity award intended to align management incentives with shareholder interests. It does not change the company’s capital structure in a material way and is unlikely to affect near-term financial performance or valuation.